240 related articles for article (PubMed ID: 37529607)
1. Therapeutic response to pazopanib: case report and literature review on molecular abnormalities of aggressive prolactinomas.
Medina EJ; Zohdy YM; Porto E; Revuelta Barbero JM; Bray D; Maldonado J; Rodas A; Mayol M; Morales B; Neill S; Read W; Pradilla G; Ioachimescu A; Garzon-Muvdi T
Front Endocrinol (Lausanne); 2023; 14():1195792. PubMed ID: 37529607
[TBL] [Abstract][Full Text] [Related]
2. Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma.
Miao Y; Li C; Guo J; Wang H; Gong L; Xie W; Zhang Y
Mol Genet Genomic Med; 2019 Dec; 7(12):e1022. PubMed ID: 31692290
[TBL] [Abstract][Full Text] [Related]
3. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Cooper O; Mamelak A; Bannykh S; Carmichael J; Bonert V; Lim S; Cook-Wiens G; Ben-Shlomo A
Endocrine; 2014 Jun; 46(2):318-27. PubMed ID: 24287797
[TBL] [Abstract][Full Text] [Related]
4. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
5. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.
Murakami M; Mizutani A; Asano S; Katakami H; Ozawa Y; Yamazaki K; Ishida Y; Takano K; Okinaga H; Matsuno A
Neurosurgery; 2011 Jun; 68(6):E1761-7; discussion E1767. PubMed ID: 21389894
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
7. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
8. Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma.
Coopmans EC; van Meyel SWF; Pieterman KJ; van Ipenburg JA; Hofland LJ; Donga E; Daly AF; Beckers A; van der Lely AJ; Neggers SJCMM
Eur J Endocrinol; 2019 Aug; 181(2):K21-K27. PubMed ID: 31167168
[TBL] [Abstract][Full Text] [Related]
9. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
10. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
11. Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.
Gao H; Wang F; Lan X; Li C; Feng J; Bai J; Cao L; Gui S; Hong L; Zhang Y
BMC Cancer; 2015 Apr; 15():272. PubMed ID: 25884948
[TBL] [Abstract][Full Text] [Related]
12. EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Cooper O; Bonert VS; Rudnick J; Pressman BD; Lo J; Salvatori R; Yuen KCJ; Fleseriu M; Melmed S
J Clin Endocrinol Metab; 2021 Jan; 106(2):e917-e925. PubMed ID: 33150390
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas Resistant to Dopamine Agonists: Pathophysiology and Treatment.
Shimon I
Arch Med Res; 2023 Dec; 54(8):102883. PubMed ID: 37689507
[TBL] [Abstract][Full Text] [Related]
14. Expression profiling of O(6) methylguanine-DNA-methyl transferase in prolactinomas: a correlative study of promoter methylation and pathological features in 136 cases.
Jiang XB; Hu B; He DS; Mao ZG; Wang X; Song BB; Zhu YH; Wang HJ
BMC Cancer; 2015 Sep; 15():644. PubMed ID: 26400193
[TBL] [Abstract][Full Text] [Related]
15. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin is reduced in membranes of human prolactinoma cells and it is inhibited by temozolomide in prolactin secreting tumor models.
Demarchi G; Valla S; Perrone S; Chimento A; Bonadeo N; Vitale DL; Spinelli FM; Cervio A; Sevlever G; Alaniz L; Berner S; Cristina C
Tumour Biol; 2022; 44(1):85-105. PubMed ID: 35811548
[TBL] [Abstract][Full Text] [Related]
17. Clinical management of difficult to treat macroprolactinomas.
Sahakian N; Castinetti F; Dufour H; Graillon T; Romanet P; Barlier A; Brue T; Cuny T
Expert Rev Endocrinol Metab; 2019 May; 14(3):179-192. PubMed ID: 30913932
[TBL] [Abstract][Full Text] [Related]
18. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
19. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications.
Biagetti B; Simò R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]